Posts Tagged ‘results’
Applied Nanoscience Reports Positive H1N1, Rhinovirus Test Results And Strides Toward Commercialization Of NanoFense Protective Face Mask
Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration company, today announced that it has received extremely positive test results on the effectiveness of the disposable NanoFense™ Protective Face Mask when challenged with the current swine influenza virus (H1N1)…
Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC), a CSC Company (NYSE:CSC), presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives…
Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
Alkermes, Inc. (NASDAQ: ALKS) announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC)…
First Results In United States In 20 Years From Clinical Trials Of Smoked Cannabis
Researchers from the University of California’s Center for Medicinal Cannabis Research (CMCR) have found “reasonable evidence that cannabis is a promising treatment” for some specific, pain-related medical conditions. Their findings, presented to the California legislature and public, are included in a report available on the CMCR web site at http://www.cmcr.ucsd.edu…
SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
Phosphagenics Announces Positive Results From Phase 1B Study Of Transdermal Oxycodone Patch
Phosphagenics Limited (“Phosphagenics”) (ASX: POH; OTCQX: PPGNY) today announced positive results from a Phase 1B clinical study using the Company’s patented TPM? (Targeted Penetration Matrix) for the transdermal delivery of oxycodone…
SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza
ImmuneRegen BioSciences Inc.?, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced additional positive results from a recent study that evaluated its lead anti-influenza drug, Homspera?, in ferrets…
SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus In Initial Pilot Animal Study
SinoFresh HealthCare, Inc. (PINKSHEETS: SFSH) announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 (“swine flu”) virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals.
Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch
Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (OTC BB: WPHM) today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company’s patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN). The study successfully demonstrated the efficacy of Civamide Patch 0.
Rx Drug Compare
Translator
By N2H